SGEN starts lung cancer Phase II

Seattle Genetics (SGEN) began a U.S. Phase II trial of its SGN-15 monoclonal antibody drug conjugate alone and in combination with Taxotere to treat non-small cell lung carcinoma in up to 60 patients....